Advertisement

PharmacoEconomics & Outcomes News

, Volume 821, Issue 1, pp 15–15 | Cite as

Gefitinib, erlotinib preferred in EGFR-mutation+ NSCLC in China

Clinical study

Reference

  1. Cai H, et al. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-Positive Non-Small Cell Lung Cancer in China. Clinical Therapeutics : 11 Jan 2019. Available from: URL: http://doi.org/10.1016/j.clinthera.2018.12.007

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations